Somewhat Positive Press Coverage Somewhat Unlikely to Impact AC Immune SA (ACIU) Stock Price
News articles about AC Immune SA (NASDAQ:ACIU) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AC Immune SA earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.1463667974302 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of AC Immune SA from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. Credit Suisse Group set a $18.00 price target on shares of AC Immune SA and gave the stock a “buy” rating in a report on Wednesday, July 19th.
AC Immune SA (NASDAQ ACIU) traded down 0.10% on Friday, hitting $10.24. 64,044 shares of the company traded hands. The firm’s 50 day moving average price is $10.46 and its 200 day moving average price is $10.46. AC Immune SA has a 1-year low of $9.06 and a 1-year high of $19.97. The firm’s market capitalization is $582.88 million.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact AC Immune SA (ACIU) Stock Price” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-ac-immune-sa-aciu-stock-price.html.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.